666715-07-7

Upstream product

• 666715-02-2 (2R,4S)-4-[(2E,7E)-(4S,9S)-4,8-Dimethyl-6-methylene-9-(2-trimethylsilanyl-ethoxymethoxy)-undeca-2,7-dienyl]-2-(2,4,6-trimethyl-phenyl)-[1,3]dioxolane-4-carboxylic acid methyl ester 
• 666715-14-6 (2R,4S)-4-((2E,7E)-(4S,9S)-9-Hydroxy-4,8-dimethyl-6-methylene-undeca-2,7-dienyl)-2-(2,4,6-trimethyl-phenyl)-[1,3]dioxolane-4-carboxylic acid methyl ester 
• 666715-15-7 (2R,4S)-4-((2E,7E)-(4S,9S)-9-Acetoxy-4,8-dimethyl-6-methylene-undeca-2,7-dienyl)-2-(2,4,6-trimethyl-phenyl)-[1,3]dioxolane-4-carboxylic acid methyl ester 

Downstream Products

• 666715-16-8 (11E,16E)-(2R,5S,7R,10S,15S)-10-Ethyl-7,11,15-trimethyl-13-methylene-2-(2,4,6-trimethyl-phenyl)-1,3,9-trioxa-spiro[4.13]octadeca-11,16-diene-6,8-dione 

Relevant academic research and scientific papers

Novel galbonolide derivatives as IPC synthase inhibitors: Design, synthesis and in vitro antifungal activities

A series of novel galbonolide derivatives having a modified methyl enol ether moiety were prepared in total synthetic procedures and evaluated for their in vitro antifungal activities. The antifungal activity was labile to modification of the enol ether functionality and almost all of the modified compounds lacked the activity except for the analogue with an introduction of a methylthio group at the C-6 position, which retained a modest antifungal potency against Cryptococcus neoformans.